NCT05163717View on ClinicalTrials.gov

INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 23, 2022

Primary Completion Date

March 31, 2023

Study Completion Date

April 24, 2023

Conditions
Agitation in Adolescents and Young Adults With ASD
Interventions
COMBINATION_PRODUCT

INP105

A single 5 mg dose of POD-OLZ (Precision Olfactory Delivery \[POD®\]-olanzapine)

COMBINATION_PRODUCT

Placebo

A single dose of POD-placebo (Precision Olfactory Delivery \[POD®\]-placebo)

Trial Locations (2)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

04102

Maine Behavioral Healthcare, Portland

Sponsors
All Listed Sponsors
lead

Impel Pharmaceuticals

INDUSTRY